NASDAQ:BPMC Blueprint Medicines (BPMC) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free BPMC Stock Alerts $94.00 +3.27 (+3.60%) (As of 12:52 PM ET) Add Compare Share Share Today's Range$90.47▼$94.3450-Day Range$85.18▼$99.7952-Week Range$43.89▼$101.00Volume242,322 shsAverage Volume757,769 shsMarket Capitalization$5.75 billionP/E RatioN/ADividend YieldN/APrice Target$85.43 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Blueprint Medicines alerts: Email Address Blueprint Medicines MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside5.8% Downside$85.43 Price TargetShort InterestBearish6.94% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.05Based on 8 Articles This WeekInsider TradingSelling Shares$8.31 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.41) to ($2.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.51 out of 5 starsMedical Sector866th out of 908 stocksPharmaceutical Preparations Industry409th out of 425 stocks 2.3 Analyst's Opinion Consensus RatingBlueprint Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 8 buy ratings, 2 hold ratings, and 3 sell ratings.Amount of Analyst CoverageBlueprint Medicines has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.94% of the outstanding shares of Blueprint Medicines have been sold short.Short Interest Ratio / Days to CoverBlueprint Medicines has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Blueprint Medicines has recently decreased by 2.75%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldBlueprint Medicines does not currently pay a dividend.Dividend GrowthBlueprint Medicines does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BPMC. Previous Next 1.1 News and Social Media Coverage News SentimentBlueprint Medicines has a news sentiment score of -0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Blueprint Medicines this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for BPMC on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Blueprint Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Blueprint Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,314,163.00 in company stock.Percentage Held by InsidersOnly 3.88% of the stock of Blueprint Medicines is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Blueprint Medicines are expected to grow in the coming year, from ($5.41) to ($2.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Blueprint Medicines is -10.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Blueprint Medicines is -10.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBlueprint Medicines has a P/B Ratio of 42.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Blueprint Medicines Stock (NASDAQ:BPMC)Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Read More BPMC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BPMC Stock News HeadlinesApril 2, 2024 | insidertrades.comBlueprint Medicines Co. (NASDAQ:BPMC) CFO Michael Landsittel Sells 5,000 SharesMarch 27, 2024 | insidertrades.comJeffrey W. Albers Sells 11,033 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) StockApril 26, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. April 26, 2024 | markets.businessinsider.comBlueprint Medicines Corporation: A Strong Buy on Robust Pipeline and Market Potential for Mast Cell Disease TreatmentsApril 26, 2024 | markets.businessinsider.comThe Analyst Verdict: Blueprint Medicines In The Eyes Of 7 ExpertsApril 22, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Hold Rating on Blueprint Medicines (BPMC)April 18, 2024 | prnewswire.comBlueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024April 11, 2024 | prnewswire.comBlueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted TherapeuticsApril 26, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.April 10, 2024 | markets.businessinsider.comDecoding 6 Analyst Evaluations For Blueprint MedicinesApril 10, 2024 | markets.businessinsider.comBlueprint Medicines Buy Rating: Promising BLU-222 Efficacy and Strong Financial OutlookApril 4, 2024 | prnewswire.comBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 29, 2024 | finance.yahoo.comBlueprint Medicines Corporation (NASDAQ:BPMC): When Will It Breakeven?March 21, 2024 | investing.comBlueprint Medicines executive sells stock worth over $399kMarch 21, 2024 | nasdaq.comFirst Week of May 17th Options Trading For Blueprint Medicines (BPMC)March 16, 2024 | finance.yahoo.comBPMC Apr 2024 90.000 putMarch 15, 2024 | finance.yahoo.comBlueprint Medicines Corp's Chief Commercial Officer Sells Company SharesMarch 15, 2024 | finance.yahoo.comBPMC Apr 2024 45.000 putMarch 4, 2024 | finance.yahoo.comBPMC Apr 2024 120.000 callMarch 4, 2024 | finance.yahoo.comBPMC Dec 2024 115.000 callMarch 4, 2024 | finance.yahoo.comBPMC Jun 2024 115.000 callMarch 3, 2024 | finance.yahoo.comBPMC Mar 2024 100.000 putFebruary 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Blueprint Medicines on Strong Ayvakit Clinical Performance and Promising PipelineFebruary 26, 2024 | markets.businessinsider.comBlueprint Medicines Receives Sell Rating Amidst Modest Polypharmacy Reduction and Negative Share Price ProjectionsFebruary 26, 2024 | markets.businessinsider.comBlueprint Medicines: Sell Rating Justified by Gavreto Divestiture and Strategic ShiftFebruary 24, 2024 | msn.comBlueprint Medicines (BPMC) Price Target Increased by 11.02% to 99.12February 23, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Blueprint Medicines (BPMC)See More Headlines Receive BPMC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today4/26/2024Next Earnings (Confirmed)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BPMC CUSIPN/A CIK1597264 Webwww.blueprintmedicines.com Phone(617) 374-7580FaxN/AEmployees655Year Founded2011Price Target and Rating Average Stock Price Target$85.43 High Stock Price Target$115.00 Low Stock Price Target$43.00 Potential Upside/Downside-5.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($8.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-506,980,000.00 Net Margins-203.30% Pretax Margin-202.91% Return on Equity-191.56% Return on Assets-45.25% Debt Debt-to-Equity Ratio1.60 Current Ratio3.76 Quick Ratio3.66 Sales & Book Value Annual Sales$249.38 million Price / Sales22.27 Cash FlowN/A Price / Cash FlowN/A Book Value$2.15 per share Price / Book42.20Miscellaneous Outstanding Shares61,200,000Free Float58,825,000Market Cap$5.55 billion OptionableOptionable Beta0.63 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMs. Kathryn Haviland (Age 48)President, CEO & Director Comp: $1.17MMr. Alexis A. Borisy A.M. (Age 52)Co-Founder & Director Comp: $50kMr. Michael Landsittel (Age 52)Chief Financial Officer Comp: $785.36kMs. Christina Rossi (Age 47)Chief Operating Officer Comp: $875.22kMs. Tracey L. McCain Esq. (Age 56)Executive VP, Chief Legal & Compliance Officer and Secretary Comp: $764.9kDr. Fouad Namouni M.D. (Age 55)President of Research & Development Comp: $916.4kMs. Ariel Hurley (Age 50)Senior VP, Finance & Principal Accounting Officer Dr. Christopher K. Murray Ph.D. (Age 60)Senior VP of Technical Operations and Chief Technical Operations & Quality Officer Comp: $338.37kDr. Percy H. Carter M.B.A. (Age 53)Ph.D., Chief Scientific Officer Comp: $761.15kJenna CohenSenior Director & Head of Investor RelationsMore ExecutivesKey CompetitorsApellis PharmaceuticalsNASDAQ:APLSIonis PharmaceuticalsNASDAQ:IONSOrganon & Co.NYSE:OGNElanco Animal HealthNYSE:ELANForty SevenNASDAQ:FTSVView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Sold 94,549 shares on 4/24/2024Ownership: 0.286%Raymond James Financial Services Advisors Inc.Bought 2,884 shares on 4/23/2024Ownership: 0.060%Handelsinvest InvesteringsforvaltningSold 2,012 shares on 4/19/2024Ownership: 0.006%Diversified Trust CoBought 498 shares on 4/18/2024Ownership: 0.024%Allspring Global Investments Holdings LLCBought 2,303 shares on 4/18/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions BPMC Stock Analysis - Frequently Asked Questions Should I buy or sell Blueprint Medicines stock right now? 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last twelve months. There are currently 3 sell ratings, 2 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BPMC shares. View BPMC analyst ratings or view top-rated stocks. What is Blueprint Medicines' stock price target for 2024? 14 Wall Street analysts have issued 12-month price targets for Blueprint Medicines' shares. Their BPMC share price targets range from $43.00 to $115.00. On average, they anticipate the company's stock price to reach $85.43 in the next year. This suggests that the stock has a possible downside of 5.8%. View analysts price targets for BPMC or view top-rated stocks among Wall Street analysts. How have BPMC shares performed in 2024? Blueprint Medicines' stock was trading at $92.24 at the start of the year. Since then, BPMC stock has decreased by 1.6% and is now trading at $90.73. View the best growth stocks for 2024 here. Are investors shorting Blueprint Medicines? Blueprint Medicines saw a decline in short interest in March. As of March 31st, there was short interest totaling 4,370,000 shares, a decline of 15.1% from the March 15th total of 5,150,000 shares. Based on an average daily volume of 786,700 shares, the short-interest ratio is currently 5.6 days. View Blueprint Medicines' Short Interest. When is Blueprint Medicines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our BPMC earnings forecast. How can I listen to Blueprint Medicines' earnings call? Blueprint Medicines will be holding an earnings conference call on Thursday, May 2nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Blueprint Medicines' earnings last quarter? Blueprint Medicines Co. (NASDAQ:BPMC) announced its earnings results on Thursday, February, 15th. The biotechnology company reported ($1.82) earnings per share for the quarter, topping the consensus estimate of ($2.04) by $0.22. The biotechnology company had revenue of $71.96 million for the quarter, compared to the consensus estimate of $67.34 million. Blueprint Medicines had a negative net margin of 203.30% and a negative trailing twelve-month return on equity of 191.56%. The company's quarterly revenue was up 85.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($2.65) EPS. What ETFs hold Blueprint Medicines' stock? ETFs with the largest weight of Blueprint Medicines (NASDAQ:BPMC) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Tema Oncology ETF (CANC), WisdomTree BioRevolution Fund (WDNA), Virtus LifeSci Biotech Products ETF (BBP), Harbor Corporate Culture Small Cap ETF (HAPS), BlackRock Future Health ETF (BMED), Range Cancer Therapeutics ETF (CNCR) and Loncar China Biopharma ETF (CHNA). What is Kate Haviland's approval rating as Blueprint Medicines' CEO? 16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend. What other stocks do shareholders of Blueprint Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR). When did Blueprint Medicines IPO? Blueprint Medicines (BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Blueprint Medicines' major shareholders? Blueprint Medicines' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.29%), Raymond James Financial Services Advisors Inc. (0.06%), Diversified Trust Co (0.02%), Handelsinvest Investeringsforvaltning (0.01%), Clarus Wealth Advisors (0.00%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Ariel Hurley, Christina Rossi, Christopher K Murray, Debra Durso-Bumpus, Fouad Namouni, George Demetri, Jeffrey W Albers, Kate Haviland, L Becker Hewes, Mark Alan Goldberg, Michael Landsittel, Percy H Carter and Tracey L Mccain. View institutional ownership trends. How do I buy shares of Blueprint Medicines? Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BPMC) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
